You are here: Industry Insights > lymphoma

News List

Lymphoma drug, pralatrexate outperforms remdesivir against COVID-19: Study expresspharma
January 04, 2021
However, this chemotherapy drug can prompt significant side effects so immediate use for COVID-19 patients is not guaranteed, said researchers.
Innovent Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas prnasia
December 08, 2020
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced data from two ongoing ..
Volition Veterinary Diagnostics Development LLC Announces Product Data Regarding its Nu.Q™ Vet Cancer Screening Test in Lymphoma and Hemangiosarcoma to be Presented at the 2020 VCS Virtual Annual Conf prnasia
October 21, 2020
VolitionRx Limited, a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, is presenting two abstracts with new data on its ...
NICE backing for Takeda's Adcetris for rare lymphoma pharmatimes
July 14, 2020
Takeda's Adcetris (brentuximab vedotin) has won the backing of the National Institute for Health and Care Excellence (NICE) as a treatment for untreated systemic anaplastic large cell lymphoma (sALCL), a rare type of lymphoma.
NICE recommends Adcetris (brentuximab vedotin) for treatment of rare lymphoma europeanpharmaceuticalreview
July 14, 2020
The recommendation of Adcetris (brentuximab vedotin) represents the first new frontline therapy for systemic anaplastic large cell lymphoma (sALCL) in several decades.
Takeda gets expanded EC approval for lymphoma drug Adcetris pharmaceutical-business-review
May 19, 2020
Takeda Pharmaceutical has secured expanded approval from the European Commission (EC) for its Adcetris in combination with CHP (cyclophosphamide, doxorubicin, prednisone).
NICE does not recommend polatuzumab vedotin to treat lymphoma europeanpharmaceuticalreview
March 03, 2020
NICE has formed a negative opinion for Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine to treat diffuse large B-cell lymphoma.
Rafael Expands CPI-613 Trial americanpharmaceuticalreview
December 27, 2019
Rafael Pharmaceuticals announced the expansion of its Phase 2 clinical trial of CPI-613® (devimistat) for patients with relapsed or refractory Burkitt’s lymphoma/leukemia.
Leukemia, lymphoma squarely in sights of new class of drugs worldpharmanews
December 09, 2019
UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of ...
Incidence of Hodgkin Lymphoma Up in Least Deprived Areas drugs
September 26, 2019
Individuals living in the most affluent areas of the United Kingdom seem to have an increased incidence of Hodgkin lymphoma (HL), according to a study published in the August issue of BMJ Open.

Previous page 1 2 3 4 5 Next page